ENSB news

Latest 2 stories · newest Sep 29, 2026

ENSB

Ensysce amends Series C preferred stock designation

Ensysce Biosciences filed a certificate of amendment to delete a provision and references for Section 6.5.3 from its Series C preferred stock designation.

Other Sep 29, 2026 sentiment 0.00 SEC filing ↗

ENSB

Ensysce Biosciences signs Merger Agreement with Cy Biopharma

Ensysce Biosciences, Inc. entered into an agreement and plan of merger with Cy Biopharma, Inc. The deal documents a strategic combination filed with the SEC on August 5, 2026.

M&A Aug 6, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ENSB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ENSB/newsSTART FREE